AllianceBernstein’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

AllianceBernstein’s Portfolio TBRA Stock Details TBRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-189	Closed	-$2K	–	3460
2015 Q1	$2K	Hold	189	–	–	﹤0.01%	3487
2014 Q4	$2K	Hold	189	–	–	﹤0.01%	3416
2014 Q3	$2K	Sell	189 -189	-50%	-$3.73K	﹤0.01%	3393
2014 Q2	$23K	Buy	+378	New	+$23K	﹤0.01%	3220

Other funds holding TBRA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CPV

Canaan Partners VII Westport, Connecticut $32.3M AUM 154.97% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AllianceBernstein's TBRA Position: Q2 2015 in Review

AllianceBernstein sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q2 2015, closing a stake of 189 shares — an estimated $2K sold.

AllianceBernstein first reported a position in TBRA in Q2 2014 and held it in 4 quarters. The position peaked at $23K in Q2 2014. 42 funds tracked by Wall St. Rank hold TBRA as of Q2 2015.

AllianceBernstein reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
AllianceBernstein sold 189 Tobira Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $2K.
AllianceBernstein first reported a position in Tobira Therapeutics, Inc. Common Stock in Q2 2014 and held it in 4 quarters.
AllianceBernstein's Tobira Therapeutics, Inc. Common Stock position peaked at $23K in Q2 2014.
42 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q2 2015.

Based on AllianceBernstein's 13F filing for Q2 2015, filed 14 Aug 2015.